









tDeveloping Innovative Clinicians and
Biomedical Engineers
A Case Study
Youseph Yazdi, PhD, MBAIntroduction
In addressing the challenge of rising healthcare costs,medical technology innovation is routinely pre-sented as both a villain responsible for high health-
are costs and a savior that can substantially reduce over-
ll costs and improve outcomes. Although many
ealthcare stakeholders are striving to direct innovation
o realize the latter, positive potential, a critical element
hat generally has been overlooked is the development of
he innovators themselves. The pace and success of this
ffort will depend on the development of a new genera-
ion ofmedtech innovation leaders that can flourish in an
nvironment that is very different from the one in which
he medical device industry emerged.
The Johns Hopkins Approach
The Center for Bioengineering Innovation & Design
(CBID) is a new program (CBID.bme.jhu.edu) within
the Department of Biomedical Engineering at Johns
Hopkins University (JHU). The CBID has the dual
mission of (1) educating and developing the next gen-
eration of medtech innovation leaders and (2) creating
and developing healthcare solutions that have high
potential for clinical impact and commercial viability
worldwide. The CBID is one example of a new breed of
academically based medtech innovation centers fol-
lowing the lead of the Stanford Biodesign program.
Each program has unique characteristics, and CBID
has elements that are particularly well suited to ad-
dressing the nation’s healthcare costs challenges.
The original promise of the fıeld of engineering was to
be a bridge between human knowledge and human need.
Most traditional engineering graduate programs today
are focused on creating new knowledge, leaving the task
of understanding market needs and bridging the gap to
industry. This is nowhere more visible than in the fıeld of
biomedical engineering, wherein the growth of funding
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sion of new discoveries and technologic developments in
all areas of the biomedical sciences, many of which have
great promise to revolutionize health care if translated
into practical solutions.
Most research proposals describe how their results po-
tentially could affect clinical or other societal needs.
However, the traditional approach (of fırst developing a
new technology and then seeking out a problem it can
solve) has contributed to the perception that medical
technological innovation unnecessarily raises the com-
plexity and cost of care. Paradoxically, the perception of
clinical and societal benefıt is often based on a shared
conviction that more-advanced technology is inherently
better. Graduates of academic biomedical programs are
well trained to be scientists and thereby to continue this
tradition of knowledge creation, but they are, with rare
exception, not trained in the skills and perspectives
needed to understand healthcare needs and create prac-
tical solutions.
The Center for Bioengineering Innovation
& Design Master’s Program
Applicants to the CBIDMaster of Science in Engineering
(MSE) program are selected from a wide range of disci-
plines based on technical skill, analytic ability, creativity,
and an eagerness to understand the perspectives of other
stakeholders in the healthcare system. The 1-year CBID
MSE program puts students in direct contact with all key
stakeholders critical to developing medical technology
solutions, including scientists, clinicians, regulatory ex-
perts, reimbursement experts, investors, industry insid-
ers, and patients. The program begins with a week-long
“boot camp” to familiarize students with the skills needed
to carefully observe and analyze issues in clinical settings.
Then, over a 2-month period, students complete a
series of clinical rotations at the JHU Medical School,
shadowing clinicians in a variety of settings, and re-
viewing with them and the CBID faculty their observa-
tions and potential ideas for medtech projects. These
ideas are vetted based on the criteria of clinical impact
and commercial viability if the need is addressed suc-
cessfully. At this stage, students do not focus on spe-
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they do rely on their intuition to judge the overall
feasibility of solving a given healthcare challenge.
Global Health Innovation
Up to this point in the curriculum, the students have devel-
oped insights for innovation thatwould be appropriate for a
top-rankedmedical center suchas JohnsHopkinsMedicine,
but not the type of innovation that addresses the challenges
of affordability, training, and access in extremely cost-
constrained environments. To start them on the path of
developing this critical perspective, student teams travel to
rural healthcare facilities in developing countries such as
India, Nepal, Tanzania, and Kenya. The CBID’s principal
partner is the nonprofıt JHU-affıliate Jhpiego, an interna-
tional nonprofıt health organization. For more than 35
years, in more than 100 countries, Jhpiego has empowered
front-line health workers by designing and implementing
effective, low-cost, hands-on solutions to strengthen the de-
livery of healthcare services for women and their families.
Another major CBID partner is Laerdal Global Health, an
organization dedicated to innovation that saves the lives of
mothers and newborns.
This global health stage of the CBID program serves two
goals. The fırst goal is to create anddevelop innovations that
address the unique challenges of resource-poor healthcare
systems. The second goal is for the students, faculty, and
clinical advisers to think in a newway about the device- and
systems-level costs of medical innovation. The aim is to
develop innovators who do not have an “us versus them”
mindset toward healthcare innovation. They should be able
to bring the best practices of the developed world to their
global health projects, and techniques for innovating for
low-resource environments to their developed-world proj-
ects. This combined experience of understanding and inno-
vating for both advanced and low-resource healthcare sys-
tems develops innovators who are better equipped to
succeed in both, and to develop cost-effective solutions for
advancedmarkets.
Focus on Delivery of a Solution
Once students complete their Global Health rotations, po-
tential developed-world and global medical technology
projects (which are done in parallel) undergo a rigorous
vetting process based on two criteria: clinical impact and
likelihood of successful translation into clinical use. In the
case of developed-world devices,meeting the criteriameans
creating an innovation that has strong commercial viability.
This process leads to project selection and the formation of
design teams,which include students, clinicians, and faculty
members. Each team receives fınancial resources andmen-
toring from a network of real-world practitioners ranging
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property issues to experienced medical technology engi-
neers, investors, and product development experts. They
also complete a three-semester sequence of courses focused
on the business of biomedical innovation, a course on FDA
regulation of medical devices (taught mainly by staff from
the FDA), and other electives. Each team must deliver (for
both projects) an innovative solution that successfully
addresses relevant performance, cost, and usability
constraints.
By the end of the initial program year, the teams must
complete prototypes that demonstrate proof-of-concept,
and a business plan that outlines how their devices can be
made and delivered to patients in a commercially successful
and sustainable manner. Global health projects are particu-
larly challenging in this respect. After the initial year, CBID
has several partnerships in place to take themost-promising
innovations to the next level of development. Having these
partnerships established early in the process provides op-
portunities formentorship and guidance fromdownstream
development partners and allows students to receive feed-
back regarding customer andmarket needs.
The CBID MSE program borrows from successful
models in various universities, including Stanford’s
BioDesign program and Johns Hopkins’ own Biomedical
Engineering senior design teams courses. While the
CBID faculty work hard to ensure teams work on worthy
healthcare challenges, one cannot force innovation. If
one-fourth of projects product innovations worthy of
further development, that would be a great track record.
So far, over the past 3 years, teams have wonmajor major
design and business plan competitions and grants, and
about one-fourth of CBID projects have received follow-
on support.
A Better Process for High-Risk Early-Stage
Development
In addition to preparing a cadre of medical technology
innovators, the CBID program also provides a lower-cost
path for higher-risk early-stage medical technology proj-
ects. Project portfolio managers in industry are often
forced to sideline some of theirmost exciting innovations
in an effort to balance cost and risk, to the detriment
of patients. CBID design teams can take a high-risk
innovation-driven project from selection to proof-of-
concept at a fraction of the cost of doing similar work in
industry. Students benefıt greatly, because they are better
engaged creatively when they are working on real-world
challenges with a chance of actual societal impact. In
addition to project ideas, CBID partner companies pro-
vide mentoring and in-kind support, and may later
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Conclusion
Mostmedical device innovations have their genesis in the
ideas of clinicians. Most clinicians, however, have little
knowledge of how to further develop their ideas. Each
year, through their integration into one of 20 CBIDMSE
and undergraduate design teams, they develop their skills
and experience inmany aspects of medical device design,
development, and commercialization. Although CBID
engineers and clinicians are not all expected to become
entrepreneurs, their experience at CBID allows them to
be effectivehealthcare costs and improve access and outcomes
through innovation.
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